Methods of treating patients suffering from movement disorders

Abstract

The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A 2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A 2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A 2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A 2A receptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.

1 - 50 . (canceled) 
     
     
         51 . A method of reducing or suppressing the adverse effectiveness of L-DOPA and/or dopamine agonist therapy, comprising administering an effective amount of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or a pharmaceutically salt thereof to a Parkinson's disease patient. 
     
     
         52 . The method according to  claim 51 , wherein the patient suffers from L-DOPA- or other dopaminergic agent-induced motor complications. 
     
     
         53 . The method according to  claim 52 , wherein OFF time in motor fluctuations is reduced. 
     
     
         54 . The method according to  claim 52 , wherein dyskinesias in motor complications are improved. 
     
     
         55 . A method for L-DOPA sparing treatment comprising administering to a patient in need thereof a combination of a subclinically effective amount of L-DOPA and (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or a pharmaceutically acceptable salt thereof in an amount effective to render the L-DOPA efficacious. 
     
     
         56 . A composition for L-DOPA sparing treatment comprising a subclinically effective amount of L-DOPA and (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or a pharmaceutically acceptable salt thereof in an amount of effective to render the L-DOPA efficacious. 
     
     
         57 . A method of treating Parkinson's disease and L-DOPA motor complications, comprising administering an effective amount of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or a pharmaceutically acceptable salt thereof in combination with at least one of a COMT, DA or MAO inhibitor to a patient in need thereof. 
     
     
         58 . A composition for the treatment of Parkinson's disease comprising an effective amount of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or a pharmaceutically acceptable salt thereof, and a at least one of COMT, DA or MAO inhibitor. 
     
     
         59 . A method of prolonging effective treatment of Parkinson's disease comprising administering either (i) (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or a pharmaceutically acceptable salt thereof, or (ii) (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or a pharmaceutically acceptable salt thereof and a dopamine agonist to a patient in need thereof in an amount effective to delay or remove the patient's need for add-on L-DOPA therapy. 
     
     
         60 . A method of treating movement disorders comprising administering an effective amount of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine or a pharmaceutically acceptable salt thereof to a patient in need thereof. 
     
     
         61 . The method according to  claim 60 , wherein the patient suffers from tremors, bradykinesias, shuffling gait, dystonias, dyskinesias, tardive dyskinesias or other extrapyramidal syndromes.